secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001099800-23-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q4 sales up 1% to $1.35B; adjusted EPS grows 25% to $0.64
-----------------------------------------------------------------

- Q4 TAVR sales flat at $868M; constant-currency growth 5%; U.S. procedures rose mid-single digits.
- Full-year 2022 sales $5.38B (+3%); adjusted EPS $2.48 (+12% YoY).
- Repurchased $1.7B of stock in 2022; $900M remaining under authorization.
- Q4 adjusted gross margin improved to 81.0% from 76.8% a year ago.
- Reiterated 2023 outlook: sales growth 9-12% ($5.6-$6.0B); adjusted EPS $2.45-$2.60.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/ew-20230131.htm
  HTML page:      https://secwatch.observer/filing/0001099800-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer